|
Market Closed -
OTC Markets
13:09:54 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 1.430 USD | -14.37% |
|
-.--% | +175.00% |
| Fiscal Period: December | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|
Selling General & Admin Expenses, Total | 1.12M | 673K | 1.41M | 1.82M |
R&D Expenses | 67K | 7K | 2.16M | 1.64M |
Other Operating Expenses, Total | 1.19M | 680K | 3.57M | 3.46M |
Operating Income | -1.19M | -680K | -3.57M | -3.46M |
Interest Expense, Total | -22K | -3K | -2K | - |
Interest And Investment Income | - | - | 65K | 57K |
Net Interest Expenses | -22K | -3K | 63K | 57K |
EBT, Excl. Unusual Items | -1.21M | -683K | -3.5M | -3.41M |
Impairment of Goodwill | - | - | - | -8.65M |
Asset Writedown | - | - | - | -1.04M |
EBT, Incl. Unusual Items | -1.21M | -683K | -3.5M | -13.09M |
Income Tax Expense | - | - | - | 358K |
Earnings From Continuing Operations | -1.21M | -683K | -3.5M | -13.45M |
Net Income to Company | -1.21M | -683K | -3.5M | -13.45M |
Net Income - (IS) | -1.21M | -683K | -3.5M | -13.45M |
Preferred Dividend and Other Adjustments | - | - | -1.42M | - |
Net Income to Common Incl Extra Items | -1.21M | -683K | -2.08M | -13.45M |
Net Income to Common Excl. Extra Items | -1.21M | -683K | -2.08M | -13.45M |
Per Share Items | ||||
Net EPS - Basic | -0.04 | -0.02 | -0.03 | -0.22 |
Basic EPS - Continuing Operations | -0.04 | -0.02 | -0.03 | -0.22 |
Basic Weighted Average Shares Outstanding | 28.11M | 29.36M | 60.73M | 60.73M |
Net EPS - Diluted | -0.04 | -0.02 | -0.03 | -0.22 |
Diluted EPS - Continuing Operations | -0.04 | -0.02 | -0.03 | -0.22 |
Diluted Weighted Average Shares Outstanding | 28.11M | 29.36M | 60.73M | 60.73M |
Normalized Basic EPS | -0.03 | -0.01 | -0.04 | -0.04 |
Normalized Diluted EPS | -0.03 | -0.01 | -0.04 | -0.04 |
Supplemental Items | ||||
EBITDA | -1.19M | -678K | -3.56M | -3.46M |
EBITA | -1.19M | -680K | -3.57M | -3.46M |
EBIT | -1.19M | -680K | -3.57M | -3.46M |
Effective Tax Rate - (Ratio) | - | - | - | -2.73 |
Normalized Net Income | -758K | -427K | -2.19M | -2.13M |
Non-Cash Pension Expense | 1K | 1K | 16K | 49K |
Supplemental Operating Expense Items | ||||
General and Administrative Expenses | 1.12M | 673K | 1.41M | 1.82M |
Research And Development Expense From Footnotes | 67K | 7K | 2.16M | 1.64M |
Stock-Based Comp., R&D Exp. (Total) | - | - | 1.42M | 103K |
Stock-Based Comp., G&A Exp. (Total) | 292K | 45K | 580K | 521K |
Total Stock-Based Compensation | 292K | 45K | 2M | 624K |
- Stock Market
- Stocks
- RVRC Stock
- Financials Revium Rx.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
